<div id="readability-page-1"><p>In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines, with a price target of <span id="expert-recommendation-target">$263.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Zhu covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Revolution Medicines, and Compass Therapeutics. According to TipRanks, Zhu has an average return of <span>22.8%</span> and a 56.59% success rate on recommended stocks. </p> <p>In a report released on May 7, Piper Sandler also maintained a Buy rating on the stock with a $172.00 price target.</p></div>

RVMD

LABU

SBIO

<p>LifeSci Capital analyst Charles Zhu has reaffirmed a Buy rating for Revolution Medicines (RVMD), setting a price target of $263.00. Zhu, who specializes in the Healthcare sector, has an average return of 22.8% and a success rate of 56.59% on his stock recommendations. Previously, Piper Sandler also maintained a Buy rating for RVMD with a price target of $172.00.</p>

Tip Ranks

Revolution Medicines

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Ideaya Biosciences

Compass Therapeutics

Piper Sandler Cos

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)